May’s top stories: Bausch + Lomb collaborates with IBM, RoundTable to acquire Symmetry
Bausch + Lomb collaborates with IBM to develop a new application for iPhone and iPad for surgeons who perform cataract surgery, and RoundTable signs agreement to acquire Symmetry for $140.3m. Medicaldevice-network.com wraps up the key headlines from May, 2016.
US-based eye health company Bausch + Lomb entered into collaboration with IBM to develop a new application for iPhone and iPad for surgeons who perform cataract surgery.
Claimed to be the first of its kind, the new application will enable surgeons to streamline their workflow by delivering patient information and clinical insights, as well as intraocular lens (IOL) options on a single, digital platform at the point of care.
Cataract extraction is becoming a common surgical procedure after a rise in cataracts affecting more than 22 million Americans was recorded, this is expected to rise to 30 million by 2020.
US-based operating-oriented private equity firm RoundTable Healthcare Partners (Roundtable) entered into a definitive agreement to acquire surgical instruments developer Symmetry Surgical for $140.3m.
Based in Nashville, US, Symmetry develops and markets reusable, reposable and single-use surgical instrumentation and specialty devices catering to the comprehensive need of clinicians and improved patient care.
Roundtable has reportedly committed to invest in equity and debt financing for the company with no financing conditions associated with the transaction, reported by Reuters.
US-based medical device company St Jude Medical introduced its new Trifecta valve with glide technology (GT) in the US to treat patients afflicted with unhealthy, damaged or malfunctioning aortic heart valves.
The Trifecta GT tissue valve allows an enhanced valve delivery to the patient during implantation in challenging anatomies and while performing minimally invasive surgeries.
It is designed to resist wear and tear over time, offering an improved tissue-to-tissue contact when the leaflets open and close.
US-based medical device company Luminex signed a definitive agreement to acquire Nanosphere, a molecular microbiology and molecular diagnostic company, for approximately $58m.
Following the acquisition, Luminex's existing customer base will be boosted by Nanosphere's Verigene platform, range of services and experience in the molecular microbiology market with more than 240 customers.
Luminex's current infectious disease portfolio will benefit from Nanosphere's Verigene technology, which is said to lead in the high-growth bloodstream infection segment.
A team of international, multi-institutional researchers led by Wyss Institute for Biologically Inspired Engineering at Harvard University synthetic biologist James Collins has developed a rapid paper-based diagnostic system for strain-specific detection of the Zika virus.
Claimed to be low-cost, the diagnostic system can be applied in the field to test blood, urine, or saliva samples.
In the wake of a rapid spread of the Ebola virus, Collins and his team, along with collaborators from Massachusetts Institute of Technology (MIT), the Broad Institute of Harvard and MIT, Harvard Medical School (HMS), University of Toronto, Arizona State University (ASU), University of Wisconsin-Madison (UW-Madison), Boston University (BU), Cornell University, and Addgene, in 2014, developed the diagnostic test for embedding synthetic gene networks.
The National Institute for Health and Care Excellence (NICE) in the UK published its final guidance recommending two blood tests to eliminate the occurrence of pre-eclampsia during pregnancy.
During normal pregnancy, placental growth factor (PlGF) increases, however, a lack of rise in the PlGF level, indicates that the placenta is not developing properly, marking the occurrence of pre-eclampsia.
NICE recommends Triage PlGF test (Alere) and the Elecsys immunoassay sFlt-1/PlGF ratio (Roche Diagnostics) blood tests to help detect occurrence of pre-eclampsia in women between their 20th and 35th week of pregnancy.
Israel based medical technology company HIL Applied Medical has acquired laser-based cancer therapy components developer, Nanolabz, a part of the University of Nevada, to assist in developing new cancer proton therapy systems.
University of Nevada enterprise and innovation associate vice-president Dr Ellen Purpus, who had assisted in drafting the license agreement stated that the acquisition will help in validating the research, innovation and commercialisation at the University.
HIL CEO Sagi Brink-Danan said: "Today's announcement is an important step towards the developing of our advanced cancer therapy systems.
UK-based medical device company Lightpoint Medical entered into an exclusive global license agreement with the University of Arizona for Beta Emission Tomography (BET), a molecular imaging technology.
BET was developed by Professor Harrison Barrett, Regents Professor of Radiology and Optical Science, associating with his student Yijun Ding and colleague Dr Luca Caucci at the University of Arizona Center for Gamma Ray Imaging.
Lightpoint intends to introduce the molecular imaging technology in the operating room to guide cancer surgery in real-time which previously was unavailable.
US-based medical technology company Vigilant Biosciences secured CE mark approval for their OncAlert oral cancer RAPID test (OncAlert RAPID Test) to detect a tumour-initiating and stem cell associated biomarker for head and neck cancer.
With the CE mark, the test will now be introduced in 28 countries of the European Union (EU) as well as Norway, Iceland, Liechtenstein and Switzerland.
Vigilant Biosciences chairman CEO and founder Matthew Kim said: "CE Marking of our OncAlert RAPID test is a major milestone for our company as it enables us to initiate manufacturing and sales efforts across the international community.
Medical technology company Pentax Medical introduced the Optivista EPK-i7010 video processor in the European, Middle Eastern and African (EMEA) markets to provide detailed information for accurate in-vivo diagnosis.
Claimed to be the first of its kind, the device features both digital and optical enhancements facilitating an enhanced vessel and mucosal pattern characterisation.
The new optical filter producing bandwidth-limiting light in Optivista allows the physicians both digital (i-scan surface and tone enhancements) and optical enhancement (i-scan OE).